



ACR24 Abstract Moderator Disclosures

Abstracts are non-CME content.

The following types of relationships may be deemed relevant include:

1. Advisor or Review Panel Member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/Research Support
6. Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)
7. Independent Contractor
8. Ownership Interest
9. Royalties
10. Intellectual Property/Patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Other Financial or Material Support

Abu-Amer, Yousef, PhD, MSc

Abstracts: Cytokines & Cell Trafficking
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Ahmed, Salahuddin, PhD, MSc

Abstracts: RA – Animal Models
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Al-Awqati, Mina, MD

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Ambler, William, MD

Abstracts: RA – Animal Models
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Andrade, Felipe, MD, PhD

Abstracts: Antiphospholipid Syndrome
Role: Abstract Moderator
Disclosure: Advise Connect Inspire, 2 (Terminated); Celgene, 9 (Ongoing); Hillstar Bio, Inc., 2 (Ongoing); Inova, 9 (Ongoing)

Ascherman, Dana, MD

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Askanase, Anca, MD, MPH

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity

Role: Abstract Moderator

Disclosure: AbbVie/Abbott, 2 (Ongoing); Amgen, 1 (Ongoing); AstraZeneca, 2 (Ongoing); biogen, 5 (Ongoing); Bristol-Myers Squibb(BMS), 1 (Ongoing), 5 (Ongoing); Cabaletta, 5 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing); Idorsia, 5 (Ongoing); Pfizer, 5 (Terminated); Sanofi, 5 (Ongoing); UCB, 5 (Ongoing)

Assassi, Shervin, MD, MS

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II

Role: Abstract Moderator

Disclosure: AbbVie/Abbott, 2 (Ongoing); AstraZeneca, 2 (Ongoing); aTyr, 2 (Ongoing), 5 (Ongoing); Boehringer-Ingelheim, 2 (Ongoing), 5 (Ongoing); CSL Behring, 2 (Ongoing); Janssen, 2 (Ongoing); Merck/MSD, 2 (Ongoing); TeneoFour, 2 (Terminated, August 2, 2022)

Aviña-Zubieta, J. Antonio, MD, PhD

Abstracts: Epidemiology & Public Health I

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Aydin, Sibel, MD

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes I

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Barber, Megan, MD, PhD

Abstracts: SLE – Treatment I: Cellular Therapy

Role: Abstract Moderator

Disclosure: AstraZeneca, 2 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing)

Barnas, Jennifer, MD, PhD, BS

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease I

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Barnes, Betsy, PhD

Plenary Session: Plenary II

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Bass, Anne, MD

Abstracts: Infection-related Rheumatic Disease

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Beck, David, MD, PhD

Abstracts: Genetics, Genomics & Proteomics

Role: Abstract Moderator

Disclosure: Novartis, 1 (Ongoing); Sobi, 1 (Ongoing)

Behrens, Edward, MD

Abstracts: Pediatric Rheumatology – Basic Science

Role: Abstract Moderator

Disclosure: AB2Bio, 5 (Ongoing); Sobi, 2 (Ongoing)

Bell, Richard, PhD

Abstracts: Cytokines & Cell Trafficking

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Bergman, Martin, MD, FACR, MACR

Abstracts: Patient Outcomes, Preferences, & Attitudes I

Role: Abstract Moderator

Disclosure: Abbvie, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Amgen, 1 (Ongoing), 2 (Ongoing); Bristol-Myers Squibb(BMS), 1 (Ongoing), 2 (Ongoing); GlaxoSmithKlein(GSK), 6 (Ongoing); Sanofi, 1 (Ongoing), 2 (Ongoing)

Bhattaram, Pallavi, PhD

Abstracts: Osteoarthritis & Joint Biology – Basic Science

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Bujor, Andreea, MD, PhD

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Calabrese, Leonard, DO

Abstracts: Infection-related Rheumatic Disease
Role: Abstract Moderator
Disclosure: AbbVie/Abbott, 2 (Ongoing); Amgen, 2 (Ongoing); AstraZeneca, 6 (Ongoing); Bristol-Myers Squibb(BMS), 2 (Ongoing); fate, 2 (Ongoing); Galvani, 2 (Ongoing); Genentech, 2 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing); Janssen, 2 (Ongoing), 6 (Ongoing); Novartis, 2 (Ongoing); UCB, 2 (Ongoing), 6 (Ongoing)

Caricchio, Roberto, MD

Abstracts: SLE – Etiology & Pathogenesis
Role: Abstract Moderator
Disclosure: Clade, 2 (Terminated, February 12, 2024); Kyverna, 2 (Terminated, February 28, 2023); NEOVII, 1 (Ongoing); NKarta, 2 (Terminated, October 2, 2023); Novartis, 2 (Terminated, November 13, 2023)

Chaichian, Yashaar, MD

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Biomarkers
Role: Abstract Moderator
Disclosure: Amgen, 5 (Terminated); Eli Lilly, 5 (Terminated); LuCIN, 5 (Ongoing)

Chen, Yen, PhD

Abstracts: ARP Interprofessional II: Psychology & Practice
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Chung, Lorinda, MD, MS

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III
Role: Abstract Moderator
Disclosure: Eicos Science, 1 (Ongoing), 2 (Ongoing); Eli Lilly, 1 (Ongoing), 2 (Ongoing); Genentech, 1 (Ongoing), 2 (Ongoing); IgM biosciences, 1 (Ongoing), 2 (Ongoing); Janssen, 1 (Ongoing), 2 (Ongoing); Kyverna, 1 (Ongoing), 2 (Ongoing); Mitsubishi Tanabe, 1 (Ongoing), 2 (Ongoing)

Chung, Sharon, MD, MA

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Clinical Trials
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Corrigan, Patrick, PhD, DPT

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Cron, Randy, MD, PhD

Abstracts: Pediatric Rheumatology – Basic Science
Role: Abstract Moderator
Disclosure: AbbVie/Abbott, 1 (Ongoing); Pfizer, Adjudication committees (Ongoing); Sobi, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Springer, 9 (Ongoing)

Cuda, Carla, PhD

Abstracts: SLE – Animal Models
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Cunningham, Melissa, MD, PhD

Abstracts: SLE – Etiology & Pathogenesis
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Dalvi, Sam, MD

Abstracts: RA – Treatments: New Approaches
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Davidson, Anne, MBBS, FRACP

Plenary Session: Plenary I
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Demirkaya, Erkan, MD

Abstracts: Pediatric Rheumatology – Clinical I
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Demoruelle, Kristen, MD, PhD

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Breathe: RA-ILD
Role: Abstract Moderator

Disclosure: Boehringer-Ingelheim, 5 (Ongoing); Gilead, 5 (Ongoing); Pfizer, 5 (Terminated)

Derk, Chris, MD,MS

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Dunlop-Thomas, Charmayne, MS, MPH

Abstracts: ARP Interprofessional II: Psychology & Practice

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Dyett Desir, Deborah, MD

Plenary Session: Plenary I

Role: Abstract Moderator

Disclosure: Eli Lilly, Stock (Ongoing)

Erkan, Doruk, MD, MPH

Abstracts: Antiphospholipid Syndrome

Role: Abstract Moderator

Disclosure: Abbvie, 1 (Ongoing); ACR/EULAR, 5 (Ongoing); APS ACTION, Executive Committee Co-chair (Ongoing); Argenx, 1 (Ongoing); Aurinia, 6 (Ongoing); Chugai, 1 (Ongoing); Eli Lilly, 2 (Ongoing); Exagen, 5 (Ongoing); GlaxoSmithKlein(GSK), 5 (Ongoing), 6 (Ongoing); Lupus Clinical Trials Consortium, 5 (Ongoing); NIH-NIAID, 5 (Ongoing); Up-To-Date, 9 (Ongoing)

Ermann, Joerg, MD

Abstracts: SpA Including PsA – Treatment I

Role: Abstract Moderator

Disclosure: AbbVie/Abbott, 2 (Terminated, November 12, 2022); Janssen, 2 (Terminated, September 30, 2022); Novartis, 2 (Ongoing), 5 (Ongoing); Pfizer, 2 (Terminated, December 31, 2022), 5 (Terminated, December 31, 2022)

Foeldvari, Ivan, MD

Abstracts: Pediatric Rheumatology – Clinical II

Role: Abstract Moderator

Disclosure: Eli Lilly, 2 (Ongoing); mitsubishi, 2 (Ongoing); Novartis, 2 (Ongoing)

Frech, Tracy, MD, MS

Plenary Session: Plenary II

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Gardner, Gregory, MD

Late-Breaking Late-Breaking Abstracts (L15–L20)

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

George, Michael, MD, MSc

Abstracts: Health Services Research I

Role: Abstract Moderator

Disclosure: GlaxoSmithKlein(GSK), 5 (Ongoing); Janssen, 5 (Ongoing); Pfizer, 2 (Ongoing)

Giles, Jon, MD, MPH

Abstracts: RA – Treatments II: Refining Use of Established Therapies

Role: Abstract Moderator

Disclosure: AbbVie, 2 (Ongoing); Eli Lilly, 2 (Ongoing); Novartis, 2 (Ongoing); Pfizer, 2 (Ongoing)

Gillispie-Taylor, Miriah, MD

Abstracts: Professional Education

Role: Abstract Moderator

Disclosure: Pfizer, 5 (Terminated, December 31, 2023)

Gordon, Jessica, MD, MSc

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I

Role: Abstract Moderator

Disclosure: Cumberland Pharmaceuticals, 5 (Ongoing); Merck/MSD, 5 (Ongoing)

Guma, Monica, MD, PhD

Abstracts: SpA Including PsA – Basic Science

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Hazlewood, Glen, MD, PhD, FRCPC

Abstracts: Patient Outcomes, Preferences, & Attitudes I

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Hoover, Paul, MD, PhD

Abstracts: SLE – Animal Models

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Isaacs, John, PhD, MBBS

Abstracts: RA – Etiology and Pathogenesis I

Role: Abstract Moderator

Disclosure: AbbVie/Abbott, 1 (Ongoing), 6 (Ongoing); Anaptys Bio, 2 (Ongoing); AstraZeneca, 1 (Ongoing), 2 (Ongoing); Bristol-Myers Squibb(BMS), 5 (Ongoing); Eli Lilly, 1 (Ongoing); Galapagos NV, 1 (Ongoing), 2 (Ongoing); GlaxoSmithKlein(GSK), 5 (Terminated); Istesso, 2 (Ongoing); Janssen, 5 (Terminated); Pfizer, 5 (Terminated); Revelo, 2 (Ongoing); Sanofi, 1 (Ongoing), 2 (Ongoing); Sonoma, 1 (Terminated); Topas, 2 (Ongoing)

Jafarzadeh, S. Reza, PhD

Abstracts: ARP Interprofessional I: Epidemiology & Methods

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Jeffries, Matlock, MD, FACP, FACR

Plenary Session: Plenary III

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Jonsson, Anna Helena, MD, PhD

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Kahlenberg, J. Michelle, MD, PhD

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease II

Role: Abstract Moderator

Abstracts: Innate Immunity: Molecular Insights Into Immune Dysregulation

Role: Abstract Moderator

Disclosure: AstraZeneca, 2 (Ongoing); Bristol-Myers Squibb(BMS), 2 (Ongoing), 5 (Ongoing);

Danger Bio, 2 (Ongoing); Eli Lilly, 2 (Ongoing); Exo Therapeutics, 2 (Ongoing); GlaxoSmithKlein(GSK), 2 (Ongoing); HiFiBio, 2 (Ongoing); rome therapeutics, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing)

Kamen, Diane, MD, MS

Abstracts: SLE – Treatment II: Non-Cellular Lupus Therapeutics

Role: Abstract Moderator

Disclosure: Alpine Immune Sciences, 1 (Ongoing); Equillum, 1 (Terminated)

Karmacharya, Paras, MD, MS

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes II

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Kawai, Vivian, MD

Abstracts: Epidemiology & Public Health I

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Kay, Jonathan, MD

Abstracts: RA – Treatments II: Refining Use of Established Therapies

Role: Abstract Moderator

Disclosure: Aker BioMarine AS, 5 (Terminated, May 13, 2024); Amgen, 2 (Terminated, September 15, 2023); Biogen, 5 (Ongoing); Biohaven Pharmaceuticals, 2 (Ongoing); Boehringer-Ingelheim, 2 (Ongoing); Bristol-Myers Squibb(BMS), 2 (Terminated, December 14, 2022); Fresenius Kabi, 2 (Ongoing); Galapagos, 5 (Ongoing); Kolon TissueGene, 1 (Ongoing); Novartis, 2 (Terminated, October 23, 2023); Pfizer, 2 (Terminated, November 28, 2023); Samsung Bioepis, 2 (Terminated, December 31, 2023); Sandoz, 2 (Ongoing); Teijin Pharma, 2 (Ongoing); UCB, 2 (Terminated, May 25, 2024); Yuhan, 6 (Terminated, May 20, 2023)

Keeling, Stephanie, MD

Abstracts: SLE – Treatment II: Non-Cellular Lupus Therapeutics

Role: Abstract Moderator

Disclosure: AbbVie/Abbott, 1 (Ongoing), 2 (Ongoing), 5 (Ongoing), 6 (Ongoing);

AstraZeneca, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Celltrion, 6 (Ongoing); Fresenius Kabi, 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); GlaxoSmithKlein(GSK), 1 (Ongoing), 2 (Ongoing), 6 (Ongoing); Janssen, 1 (Ongoing), 6 (Ongoing); UCB, 2 (Ongoing), 6 (Ongoing)

Kermani, Tanaz, MD, MS

Abstracts: Vasculitis – ANCA-Associated II
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Kerschbaumer, Andreas, MD, PhD

Abstracts: RA – Treatments: New Approaches
Role: Abstract Moderator
Disclosure: AbbVie/Abbott, 2 (Terminated, April 14, 2024); Boehringer-Ingelheim, medical conference attendance fee (Ongoing); Eli Lilly, conference attendance fee (Terminated), 2 (Terminated), 6 (Terminated); Galapagos, 6 (Terminated); Janssen, 2 (Ongoing), 6 (Ongoing); Merck/MSD, 6 (Terminated); Novartis, 2 (Terminated); Pfizer, 6 (Terminated); UCB, 2 (Terminated), Travel (Terminated)

Khanna, Puja, MD, MPH

Abstracts: Healthcare Disparities in Rheumatology
Role: Abstract Moderator
Disclosure: Arthroci, 5 (Ongoing); Horizon, 2 (Ongoing); Olatec, 5 (Ongoing); SOBI, 2 (Ongoing)

Koenig, Curry, MD, MS

Abstracts: Vasculitis – ANCA-Associated I
Role: Abstract Moderator
Disclosure: Amgen, 1 (Ongoing), 6 (Ongoing)

Koster, Matthew, MD, RhMSUS

Abstracts: Vasculitis – ANCA-Associated I
Role: Abstract Moderator
Disclosure: Amgen, 1 (Terminated, October 1, 2023)

Koumpouras, Fotios, MD

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes III: Targets, Outcomes & Comorbidity
Role: Abstract Moderator
Disclosure: Adicet Bio, 2 (Ongoing); Atara Bio, 2 (Ongoing)

Kronzer, Vanessa, MD, MSc

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Best Day (RA Subpopulations)
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Kuriya, Bindee, MD, MS

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Breathe: RA-ILD
Role: Abstract Moderator
Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Bad Blood (Serologic and Imaging Biomarkers)
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Kyttaris, Vasileios, MD, PhD

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease
Role: Abstract Moderator
Disclosure: Janssen, 1 (Terminated, December 14, 2023)

Lakin, Kimberly, MD, MS

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Lau, Arthur, MD

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science
Role: Abstract Moderator
Disclosure: AbbVie/Abbott, 6 (Ongoing); Amgen, 6 (Ongoing); Novartis, 6 (Ongoing); UCB, 6 (Ongoing)

LaValley, Michael, PhD

Abstracts: ARP Interprofessional I: Epidemiology & Methods
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Lee, Jiha, MD, MHS

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Best Day (RA Subpopulations)
Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Lo, Grace, MD, MSc

Abstracts: Osteoarthritis – Clinical Trials
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Malfait, Anne-Marie, MD

Abstracts: Osteoarthritis – Novel Insights from Observational Studies
Role: Abstract Moderator
Abstracts: Pain in Rheumatic Disease Including Fibromyalgia
Role: Abstract Moderator
Disclosure: Averitas, 2 (Ongoing); Orion, 5 (Ongoing)

Manfrè, Valeria, MD

Abstracts: Sjögren's Syndrome – Basic & Clinical Science
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Massarotti, Elena, MD

Abstracts: SLE – Treatment I: Cellular Therapy
Role: Abstract Moderator
Disclosure: Argenx, 2 (Terminated); Cabaletta, 2 (Terminated); Capstan Therapeutics, 2 (Terminated); EMD Serono, 1 (Ongoing); Kezar, 2 (Terminated); Otsuka, 2 (Terminated)

Mehta, Vivek, MBBS

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Mehta, Bella, MD, MS, MBBS

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Miller, Karla, MD

Abstracts: Osteoporosis & Metabolic Bone

Disease – Basic & Clinical Science

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Moghadam-Kia, Siamak, MD, MPH

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Mohan, Smriti, MD

Abstracts: Pediatric Rheumatology – Clinical I
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Mueller, Alisa, MD, PhD

Abstracts: RA – Etiology and Pathogenesis I
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Myasoedova, Elena, MD, PhD

Abstracts: Epidemiology & Public Health II
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Nagaraja, Vivek, MD, FACR

Abstracts: Measures & Measurement of Healthcare Quality
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Nelson, Meghan, DO

Abstracts: Pediatric Rheumatology – Clinical II
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Ogdie, Alexis, MD

Abstracts: SpA Including PsA – Treatment II
Role: Abstract Moderator
Disclosure: AbbVie/Abbott, 2 (Ongoing), 5 (Ongoing); Amgen, 2 (Ongoing), 5 (Ongoing); Bristol-Myers Squibb(BMS), 2 (Ongoing); Celgene, 2 (Ongoing); CorEvitas, 2 (Ongoing); Eli Lilly, 2 (Ongoing); Gilead, 2 (Ongoing); GSK,

2 (Ongoing); Janssen, 2 (Ongoing), 5 (Ongoing); Novartis, 2 (Ongoing), 5 (Ongoing); Pfizer, 2 (Ongoing), 5 (Ongoing); Takeda, 2 (Ongoing); UCB, 2 (Ongoing)

O'Neil, Liam, MD, MHS

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Bad Blood (Serologic and Imaging Biomarkers)
Role: Abstract Moderator
Disclosure: AbbVie/Abbott, 2 (Terminated); UCB, 2 (Terminated)

Padilla, Cristina, MD, MS

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Paul, Jisna, MD

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Perl, Andras, MD, PhD

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Omics
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Pinal-Fernandez, Iago, MD, PhD

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science II
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Pope, Janet, MD, FRCPC, MPH

Late-Breaking Late-Breaking Abstracts (L15–L20)
Role: Abstract Moderator
Disclosure: AbbVie, 1 (Ongoing), 2 (Ongoing)

Proudman, Susanna, MBBS

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Omics
Role: Abstract Moderator

Disclosure: Boehringer Ingelheim, 5 (Ongoing), 6 (Ongoing); Janssen, 5 (Ongoing), 6 (Ongoing)

Puravath, Abin, MD, FACP, MHS

Abstracts: SpA Including PsA – Treatment I
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Quinn, Kaitlin, MD, MHS

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Rahman, Proton, MD

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes I
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Rhee, Rennie, MD, MS

Abstracts: Vasculitis – ANCA-Associated II
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Richardson, Carrie, MD, MHS

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II
Role: Abstract Moderator
Disclosure: Cabaletta Bio, 2 (Terminated, October 1, 2023)

Ritchlin, Christopher, MD, MPH

Abstracts: SpA Including PsA – Basic Science
Role: Abstract Moderator
Disclosure: AbbVie, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Amgen, 2 (Ongoing); BMS, 2 (Ongoing); Eli Lilly, 2 (Ongoing); Gilead, 2 (Ongoing); Janssen, 2 (Ongoing); Novartis, 2 (Ongoing); Pfizer, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); UCB, 2 (Ongoing), 6 (Ongoing)

Rohekar, Sherry, MD, FRCPC

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes II
Role: Abstract Moderator

Disclosure: AbbVie/Abbott, 1 (Ongoing), 6 (Ongoing); BioJAMP, 6 (Ongoing); Celltrion, 6 (Ongoing); Eli Lilly, 2 (Ongoing), 6 (Ongoing); Fresenius Kabi, 6 (Ongoing); Janssen, 6 (Ongoing); Novartis, 2 (Ongoing), 6 (Ongoing); Pfizer, 6 (Ongoing); UCB, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing)

Rottmann, Eva, DO, RhMSUS

Abstracts: Imaging of Rheumatic Diseases
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Samuels, Jonathan, MD, RhMSUS

Abstracts: Osteoarthritis – Clinical Trials
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Sandorfi, Nora, MD

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I
Role: Abstract Moderator
Disclosure: Bristol-Myers Squibb(BMS), 2 (Ongoing); Janssen, 2 (Ongoing); Novartis, 1 (Terminated)

Scanzello, Carla, MD, PhD

Abstracts: Osteoarthritis – Novel Insights from Observational Studies
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Scher, Jose, MD

Abstracts: SpA Including PsA – Treatment II
Role: Abstract Moderator
Disclosure: Bristol-Myers Squibb(BMS), 2 (Ongoing); Janssen, 2 (Ongoing), 5 (Ongoing); UCB, 2 (Ongoing)

Schlesinger, Naomi, MD

Abstracts: Metabolic & Crystal Arthropathies
Role: Abstract Moderator
Disclosure: arthroxi, 1 (Ongoing); horizon, 1 (Ongoing); Novartis, 1 (Ongoing); Olatec, 1 (Ongoing); protalix, 1 (Ongoing); shanton, 1 (Ongoing); sobi, 1 (Ongoing)

Schnitzer, Thomas, MD, PhD, FACR

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation
Role: Abstract Moderator
Disclosure: No relevant disclosure to display

Shalen, Julia, MD

Abstracts: Professional Education
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Shenoi, Susan, MBBS, MS, RhMSUS

Plenary Session: Plenary III
Role: Abstract Moderator
Disclosure: Amgen, 2 (Terminated, February 14, 2023); Novartis, 2 (Terminated, August 1, 2023); Pfizer, 2 (Ongoing)

Simard, Julia, MSc, ScD

Abstracts: Reproductive Issues in Rheumatic Disorders
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Simpfendorfer, Kim, PhD

Abstracts: Genetics, Genomics & Proteomics
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Smith, Vanessa, MD, PhD

Abstracts: Immunological Complications of Medical Therapy
Role: Abstract Moderator
Disclosure: Argenx, 2 (Ongoing); BKC Moving Media Makers, 6 (Terminated, July 7, 2023); Boehringer-Ingelheim, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); Janssen-Cilag, 2 (Ongoing), 5 (Ongoing), 6 (Ongoing); WebMDD Global LLC, 2 (Terminated, July 12, 2023)

Smith, Judith, MD, PhD

Abstracts: Innate Immunity: Molecular Insights Into Immune Dysregulation
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Strand, Vibeke, MD

Abstracts: Immunological Complications of Medical Therapy
Role: Abstract Moderator
Disclosure: Abbvie, 2 (Ongoing); Alpine Immune Sciences, 2 (Ongoing); Alumis, 2 (Ongoing); Amgen, 2 (Ongoing); AstraZeneca, 2 (Ongoing); Bayer, 2 (Ongoing); Blackrock, 2 (Ongoing); BMS, 2 (Ongoing); Boehringer Ingelheim, 2 (Ongoing); Celltrion, 2 (Ongoing); Citryll, 2 (Ongoing); Contura, 2 (Ongoing); Fortress Biotech, 2 (Ongoing); Genentech/Roche, 2 (Ongoing); Gilead, 2 (Ongoing); GlaxoSmithKline, 2 (Ongoing); Ichnos, 2 (Ongoing); Inmedix, 2 (Ongoing); Janssen, 2 (Ongoing); Kiniksa, 2 (Ongoing); Lilly, 2 (Ongoing); Merck, 2 (Ongoing); Novartis, 2 (Ongoing); Omeros, 2 (Ongoing); Pfizer, 2 (Ongoing); Regeneron, 2 (Ongoing); R-Pharm, 2 (Ongoing); Samsung, 2 (Ongoing); Sandoz, 2 (Ongoing); Sanofi, 2 (Ongoing); Scipher, 2 (Ongoing); Setpoint, 2 (Ongoing); Sorrento, 2 (Ongoing); Spherix, 2 (Ongoing); SynAct, 2 (Ongoing); UCB, 2 (Ongoing)

Sullivan, Megan, MD, RhMSUS

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Clinical Trials
Role: Abstract Moderator
Disclosure: Amgen, 1 (Terminated, September 1, 2023)

Tayar, Jean, MD, RhMSUS, FACP, FACR

Abstracts: Imaging of Rheumatic Diseases
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Thoma, Louise, PhD, DPT

Abstracts: Health Services Research II
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Thomas, Julie, MD

Abstracts: Healthcare Disparities in Rheumatology
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Toprover, Michael, MD

Abstracts: Metabolic & Crystal Arthropathies
Role: Abstract Moderator
Disclosure: ANI Pharmaceuticals, 2 (Terminated, February 10, 2023); Horizon Pharmaceuticals, 2 (Terminated, October 13, 2023)

Tselios, Konstantinos, MD, PhD

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Biomarkers
Role: Abstract Moderator
Disclosure: Novartis, 6 (Ongoing); UCB, 6 (Ongoing)

Ugarte-Gil, Manuel, MD, MSc

Abstracts: Epidemiology & Public Health II
Role: Abstract Moderator
Disclosure: AstraZeneca, 2 (Ongoing), 6 (Ongoing); ferrer, 2 (Terminated); GlaxoSmithKlein(GSK), 6 (Terminated); Janssen, 5 (Ongoing); Tecnofarma, 2 (Ongoing)

Valenzuela, Antonia, MD, MS

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Whitfield, Michael, PhD

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science
Role: Abstract Moderator
Disclosure: No relevant disclosure to display

Widdifield, Jessica, PhD

Abstracts: Measures & Measurement of Healthcare Quality
Role: Abstract Moderator
Disclosure: No financial relationships with ineligible companies to disclose

Wise, Leanna, MD, MPH

Abstracts: Reproductive Issues in Rheumatic Disorders
Role: Abstract Moderator
Disclosure: AstraZeneca, 6 (Ongoing); Aurinia Pharma, 2 (Ongoing), 6 (Ongoing); GlaxoSmithKlein(GSK), 6 (Ongoing)

Wither, Joan, MD, PhD

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease I

Role: Abstract Moderator

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease II

Role: Abstract Moderator

Disclosure: AstraZeneca, 1 (Ongoing), 6 (Ongoing); Pfizer, Indirect salary support through a Chair award to the Division of Rheumatology at the University of Toronto (Terminated, July 1, 2022)

York, Michael, MD

Abstracts: Health Services Research I

Role: Abstract Moderator

Abstracts: Health Services Research II

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose

Zembrzuska, Hanna, MD

Abstracts: Sjögren's Syndrome – Basic & Clinical Science

Role: Abstract Moderator

Disclosure: No financial relationships with ineligible companies to disclose